Lux Biosciences Announces Multiple Presentations on LX211 at Upcoming American Academy of Ophthalmology and American Uveitis Society Annual Meetings

JERSEY CITY, NJ (October 20, 2009): Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company’s experimental drug LX211 (LUVENIQ™; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual conference and American Uveitis Society meeting being held October 24-26 in San Francisco. Lux Biosciences plans to file an NDA and MAA for marketing approvals of LX211 in the United States and Europe, respectively around year-end 2009. If approved, LX211 may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions previously inevitably associated with either severe vision loss or substantial morbidity from steroid use.

Several presentations during AAO will discuss the results of the completed LUMINATE pivotal studies for LX211 and its use in active and clinically quiescent noninfectious uveitis. These presentations include:

Sunday October 25:

• American Uveitis Society Meeting, 9-10:30 pm, JW Marriott
  “Luveniq for Sight-Threatening Non-Infectious Uveitis: Results of the LUMINATE trials”
  Presenter: Dr. C. Stephen Foster, M.D., head of the Ocular Immunology and Uveitis Foundation, Founder and President of the Massachusetts Eye Research and Surgery Institution and Clinical Professor of Ophthalmology at Harvard Medical School.

Monday October 26:

• Session: Luveniq (LX211/Voclosporin) as Corticosteroid-Sparing Therapy in Clinically Quiescent Sight-Threatening Noninfectious Uveitis: Results of the LX221-02 Study of the LUMINATE Clinical Program.
  Program # PA026 8:50 – 8:57 am, Moscone Center – West 2006
  Presenter: Bahram Bodaghi, M.D., Ph.D., Pitié Salpétrière Hospital Paris, France

• Session: Voclosporin (LX211) as Corticosteroid-Sparing Therapy for Posterior Active Sight-Threatening Noninfectious Uveitis: Results of the LX211-01 Study of the LUMINATE Program.
  Program # PA027 9:00 – 9:07 am, Moscone Center – West 2006
  Presenter: Quan D. Nguyen, M.D., of the Wilmer Eye Institute at The Johns Hopkins University, Baltimore, MD

About Lux Biosciences

Lux Biosciences, Inc. is a privately held biotechnology company focused on the treatment of ophthalmic diseases. Its submission stage project LUVENIQ is the oral formulation of a next-generation calcineurin inhibitor (voclosporin) for which positive phase 3 data have recently been obtained for the treatment of sight-threatening non-infectious uveitis. Lux Biosciences is collaborating with the team at Isotechnika Pharma who invented the molecule and develops it for other indications. The Company has several earlier stage projects based on its mixed nanomicellar ocular formulation technology, and based on its proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye.

For more information on Lux Biosciences, please visit the company’s website at www.luxbio.com.

Forward-Looking Statements

This press release is not made on behalf of, or with authorization by, any other company or issuer of securities. To the extent that this press release may refer to any other issuer of securities, Lux Biosciences, Inc. makes no statement and expresses no recommendation or other opinion about any transaction or potential transaction concerning such securities.

This press release may contain forward-looking statements, including Lux Bioscience's belief as to the medical and commercial potential of its product candidates, Lux Bioscience's plans to pursue business and regulatory strategy, and Lux Bioscience’s expectations regarding actions and decisions solely within the control and purview of other parties. These forward-looking statements involve important known and unknown risks and uncertainties, which could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the exercise of discretion by regulatory agencies and other parties, the availability to Lux Biosciences of funds and resources to pursue research and development projects, the performance of activities and generation of scientific data by parties other than Lux Biosciences, the ability of Lux Biosciences to economically manufacture and commercialize its products once approved, acceptance by the medical community of Lux Biosciences’ products once approved and the availability of alternative therapeutic agents, approval for reimbursement by third-party payors of Lux Biosciences’ products once approved, the success and timely completion of clinical trials and other scientific studies, the ability of Lux Biosciences and its licensors to defend its and their patents from infringement by third parties, and the risk that such patents may be subsequently shown to be invalid or that the practice of such patents may infringe the patents of others. Further, Lux Biosciences disclaims any undertaking to issue further press releases or otherwise advice about changes to these beliefs, plans and expectations.

###

CONTACTS:
Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201-946-0221
Ulrich.grau@luxbio.com

Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Mobile +1 415-690-0210
Jkureczka@comcast.net